Curis (CRIS) Interest Expense : $-3.24 Mil (TTM As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

What is Curis Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Curis's interest expense for the three months ended in Dec. 2023 was $ -2.02 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-3.24 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Curis's Operating Income for the three months ended in Dec. 2023 was $ -12.20 Mil. Curis's Interest Expense for the three months ended in Dec. 2023 was $ -2.02 Mil. Curis did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Curis Interest Expense Historical Data

The historical data trend for Curis's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Interest Expense Chart

Curis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-4.85

-5.10

-4.47

-4.77

-2.02

Curis Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-1.65	-0.58	-0.64	-	-2.02

Curis Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.24 Mil.

Curis (NAS:CRIS) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Curis's Interest Expense for the three months ended in Dec. 2023 was $-2.02 Mil. Its Operating Income for the three months ended in Dec. 2023 was $-12.20 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $1.49 Mil.

Curis's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Curis did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Curis (CRIS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (NAS:CRIS) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

CUS0:Germany

Address

128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421

Website

https://www.curis.com

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Executives

Jonathan B. Zung	officer: CDO	C/O EVELO BIOSCIENCES, INC., 620 MEMORIAL DRIVE, SUITE 200, CAMBRIDGE MA 02139
Anne Elizabeth Borgman	director	9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE MD 20705
John Hohneker	director	C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139
Marc Rubin	director	C/O TITAN PHARMACEUTICALS, INC., 400 OYSTER POINT BLVD., STE 505, SAN FRANCISCO CA 94080
Kenneth I Kaitin	director	C/O TUFTS CNTR FOR THE STUDY OF DRUG DEV, 75 KNEELAND ST, SUITE 1100, BOSTON MA 02111
Martyn D Greenacre	director	41 MOORES ROAD, FRAZER PA 19355
Robert Martell	officer: Head of Research & Development	4 MAGUIRE ROAD, LEXINGTON MA 02421
Diantha Duvall	officer: CFO	C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE 5TH FLOOR, CAMBRIDGE MA 02140
James E Dentzer	director, officer: President & CEO	C/O AMICUS THERAPEUTICS, INC., 6 CEDAR BROOK DRIVE, CRANBURY NJ 08512
William Steinkrauss	officer: VP, Finance & Treasurer, other: Principal Accounting Officer	C/O CURIS, INC.,, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Lori Anne Kunkel	director	C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVENUE, SUNNYVALE CA 94085
Fattaey Ali Ph.d.	officer: President & COO	C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
James R Mcnab	director	C/O CURIS, INC, 4 MAGUIRE ROAD, LEXINGTON MA 02421
Aurigene Discovery Technologies Ltd	10 percent owner	39-40 KIADB INDUSTRIAL AREA, PHASE II, ELECTRONIC CITY HOSUR ROAD, BANGALORE (KARNATAKA) K7 560100
David Tuck	officer: Sr. Vice-President	C/O CURIS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421